<?xml version="1.0" encoding="UTF-8"?>
<ref id="B13-molecules-25-02944">
 <label>13.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Panagopoulos</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Petrakis</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Panopoulou</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Trypsianis</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Penlioglou</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Pnevmatikos</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Papazoglou</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection</article-title>
  <source>J. Chemother.</source>
  <year>2020</year>
  <fpage>1</fpage>
  <lpage>5</lpage>
  <pub-id pub-id-type="doi">10.1080/1120009X.2020.1775424</pub-id>
  <?supplied-pmid 32530369?>
  <pub-id pub-id-type="pmid">32530369</pub-id>
 </element-citation>
</ref>
